A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome
NCT07629973
Acute Respiratory Distress Syndrome (ARDS), Lung Diseases
View Trial DetailsNCT Number: NCT07380997
This study is a prospective observational investigation designed to systematically characterize key microbial signatures, metabolite profiles, and gene-expression features in serum and sputum from patients with acute respiratory distress syndrome (ARDS), and to evaluate their associations with response to invasive mechanical ventilation and clinical outcomes. A total of 411 adult ARDS patients meeting the Berlin definition and receiving invasive mechanical ventilation will be enrolled; individuals with significant pre-existing pulmonary disease or a history of immunosuppression will be excluded. Blood and sputum specimens will undergo high-throughput sequencing and metabolomics, including 16S rRNA-based microbiome profiling, whole-transcriptome RNA sequencing, and targeted/untargeted metabolite quantification by LC-MS/MS. Ventilator-related parameters (e.g., tidal volume, positive end-expiratory pressure [PEEP], and respiratory system compliance) and clinical endpoints (e.g., 28-day mortality) will be integrated to establish a comprehensive multi-omics analytical framework.
Data preprocessing will include batch-effect correction, normalization, and multiple-testing adjustment with false discovery rate control (FDR < 0.05). Differential microbes, metabolites, and transcripts will be functionally interpreted using KEGG pathway and Gene Ontology (GO) enrichment analyses. Spearman correlation analyses will be performed to examine associations between omics features and ventilator parameters. Key features will be selected using LASSO regression, followed by development of random forest and support vector machine (SVM) models to predict mechanical ventilation response and the risk of ventilator-induced lung injury (VILI). Model performance will be assessed using ROC curves, area under the curve (AUC), calibration plots, and decision curve analysis.
By integrating serum and sputum multi-omics data, this study aims to identify molecular biomarkers that influence the effectiveness of mechanical ventilation and prognosis in ARDS, thereby providing evidence to support precision ventilatory strategies and individualized clinical management to improve patient outcomes. The findings are expected to deepen mechanistic understanding of ARDS pathobiology and lay a foundation for future development of multi-omics-guided diagnostic and therapeutic approaches.
Trial opening soon.
Get NotifiedAll sexes
Observational
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment (Day 0) to Day 28 post-enrollment (28 days)
All-cause mortality within 28 days after enrollment. Survival status will be ascertained via the hospital information system and, if needed, confirmed by telephone follow-up with family members. The observation window is from the date of enrollment (Day 0) through Day 28.
Ruijin Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07629973
Acute Respiratory Distress Syndrome (ARDS), Lung Diseases
View Trial DetailsNCT07713420
Acute Respiratory Distress Syndrome (ARDS), Lung Diseases
View Trial DetailsNCT07576660
Acute Respiratory Distress Syndrome (ARDS), Infections
Nanjing, Jiangsu, China
View Trial DetailsNCT07673250
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
La Jolla, California, United States
View Trial Details